诺唯赞(688105) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 was approximately CNY 1,377.88 million, remaining stable compared to the previous year[3] - Net profit attributable to shareholders of the parent company was a loss of CNY 16.97 million, an improvement from a loss of CNY 18.09 million in the previous year[3] - The basic earnings per share improved slightly to -CNY 0.04 from -CNY 0.05 in the previous year[3] Assets and Equity - The company reported a decrease in total assets by 2.56% to CNY 4,919.59 million compared to the beginning of the period[5] - Shareholders' equity attributable to the parent company decreased by 3.79% to CNY 3,795.72 million[3] Operational Factors - The company experienced a significant reduction in operating losses, attributed to various operational factors[6] - Research and development expenses saw a slight decrease year-on-year, despite increased sales expenses due to market expansion efforts[5] - The company is actively expanding its innovative business and overseas markets, which contributed to increased sales expenses[5] Tax Impact - The VAT rate for biological products increased from 3% to 13%, negatively impacting overall revenue and profitability[5] Financial Reporting - Investors are advised to note that the financial data is preliminary and unaudited, with final results to be disclosed in the annual report[7]